Calliditas Therapeutics Q4 EPADS $(0.06) Beats $(0.07) Estimate, Sales $42.41M Beat $35.86M Estimate
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics (NASDAQ:CALT) reported Q4 earnings with losses of $(0.06) per share, surpassing the $(0.07) estimate, and sales of $42.41M, exceeding the $35.86M estimate. This represents a 392.31% increase in losses from the previous year but a 5.19% increase in sales.
February 21, 2024 | 7:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calliditas Therapeutics reported better-than-expected Q4 earnings and sales, with a significant increase in losses but also a growth in sales compared to last year.
The positive earnings and sales beat are likely to be viewed favorably by investors, despite the increase in losses. The better-than-expected performance, especially in sales growth, could lead to short-term positive sentiment and potential stock price increase.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100